Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion's lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab (Herceptin(R)), vs. paclitaxel and trastuzumab alone. Progression-free survival (PFS) is the primary efficacy endpoint, with careful monitoring for cardiac safety.

Dr. Jose Baselga, Chairman & Professor of Medicine, Vall d'Hebron Institute of Oncology (V.H.I.O.), Vall d'Hebron University Hospital in Barcelona, Spain, and principal investigator for the trial, said, "I am pleased to see that the recruitment phase of the Phase III trial has now been completed. This registration trial is based on our recently published, Roche-supported study conducted by the Spanish Breast Cancer Cooperative Group (SOLTI). Results showed that Myocet, in combination with trastuzumab and paclitaxel treatment, yielded an unusually high clinical response rate and time to progression in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. "

Phase III Study Design

The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who have metastatic HER-2-overexpressing breast cancer. Eligibility criteria included no prior chemotherapy for metastatic disease, nor any trastuzumab, anthracyclines or taxanes within the previous 12 months. Eligible patients were randomized to receive either Myocet, paclitaxel and trastuzumab, or paclitaxel and trastuzumab alone in a 1:1 randomiza
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 21, 2015 Research ... addition of the "Analysis of the Global ... offering. Globally, flow cytometry remains a ... proliferation, cancer, and stem cells. But the market ... because of demand from underdeveloped nations to quantitate ...
(Date:7/28/2015)... ... 28, 2015 , ... VetStem Biopharma will be offering weekly private guided tours ... area veterinarians. , The tour and course will be given every Wednesday at 6pm ... Poway facility. Staff members are welcome to attend with their veterinarian as well. Participants ...
(Date:7/28/2015)... Tauriga Sciences, Inc. (OTCQB:  TAUG) or ("Tauriga" ... announced that its stockholders approved an increase in the ... Company from 1,000,000,000 to 2,500,000,000 at its Special Meeting ... Law Offices of Nixon Peabody LLP in Midtown Manhattan ... 480,655,929 shares of common stock represented either by proxy ...
(Date:7/28/2015)... MORRISTOWN, N.J. , July 28, 2015 /PRNewswire/ ... its second Phase 1 clinical trial with MMI-0100, ... that is being developed for pulmonary disorders characterized ... the United Kingdom , is ... study further evaluating the safety and tolerability of ...
Breaking Biology Technology:Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2
... Japan,s first second-generation drug-eluting stentNATICK, Mass., Jan. 28 ... ) announced today that it has received approval ... Welfare (MHLW) to market its TAXUS(R) Liberte(R) Paclitaxel-Eluting ... launch the product as soon as reimbursement approval ...
... Clinical Services, will lead a panel of top pharmaceutical financial experts ... CBI Forecasting & Budgeting conference. The panel will demonstrate practical ... management of clinical trial cash flow and accruals. , ... ...
... Bion Environmental Technologies, Inc. (OTC Bulletin Board: ... 2009, the Pennsylvania Infrastructure Investment Authority (PENNVEST) approved ... LLC (a wholly-owned subsidiary of Bion Environmental Technologies, ... used to construct Bion,s previously announced Kreider Farms ...
Cached Biology Technology:Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System 2Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System 3ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference 2ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference 3Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project 2Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project 3Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project 4
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... may be uncomfortable at first, but doing exercises to strengthen ... osteoarthritis is critical to your recovery. In fact, it can ... of a healthy adult your age. That,s the finding ... issue of Arthritis Care & Research . ...
... You don,t have to get wet, or seasick, to ... worldwide. Just tune in through your computer. This morning ... available to computers everywhere was launched at the California ... Barbara are involved in the project. "The Marine Science ...
... Women who have higher levels of a hormone produced ... to develop postpartum depression, a study authored by a ... identify and treat women at risk for postpartum depression ... psychology and social behavior assistant professor, and colleagues found ...
Cached Biology News:Exercise after knee replacement critical 2New version of Google Earth features California's marine protected areas 2
... Chemicon Select Tissue Arrays are intended ... individual tissues were fixed in neutral buffered ... identification and diagnosis was performed by certified ... their paraffin blocks and relocated into a ...
... 50 X-Ray System from KUBTEC is a dual ... and three dimensional representation of the specimen under ... of specimen X-ray images, the micro focus source ... of detail in standard 2D images. The 50 ...
... BTX, the leader in electroporation products and ... innovative product line for experiment optimization and ... is a breakthrough in Molecular Delivery. The ... procedures that typically limited the number of ...
... Progesterone Receptor (PR) Competitor Assay Kits ... novel progesterone receptor binding compounds using ... utilizes a fusion of glutathione transferase ... human progesterone receptor [PR-LBD(GST)] and a ...
Biology Products: